| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/13/2023 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 11/10/2023 | — | Craig-Hallum | Downgrades | Buy → Hold | |
| 11/10/2023 | 66.67% | Wedbush | $3 → $1 | Maintains | Outperform |
| 11/10/2023 | 900% | Keybanc | $8 → $6 | Maintains | Overweight |
| 08/25/2023 | 1233.33% | Oppenheimer | → $8 | Reiterates | Outperform → Outperform |
| 08/10/2023 | 400% | Wedbush | $3.5 → $3 | Maintains | Outperform |
| 04/14/2023 | 733.33% | Wedbush | → $5 | Reiterates | → Outperform |
| 03/21/2023 | 358.33% | UBS | $6 → $2.75 | Maintains | Neutral |
| 02/01/2023 | 1233.33% | Keybanc | $7 → $8 | Maintains | Overweight |
| 01/12/2023 | 1066.67% | Keybanc | $5 → $7 | Maintains | Overweight |
| 11/10/2022 | 900% | Craig-Hallum | $4 → $6 | Upgrades | Hold → Buy |
| 09/20/2022 | 733.33% | Wedbush | $3.3 → $5 | Maintains | Outperform |
| 09/20/2022 | 733.33% | Keybanc | $10 → $5 | Maintains | Overweight |
| 03/28/2022 | 2400% | Keybanc | $16 → $15 | Maintains | Overweight |
| 03/02/2022 | 900% | Roth Capital | → $6 | Downgrades | Buy → Neutral |
| 03/02/2022 | 2566.67% | Keybanc | $22 → $16 | Maintains | Overweight |
| 12/14/2021 | 1566.67% | Wedbush | $20 → $10 | Maintains | Outperform |
| 12/14/2021 | 3566.67% | Keybanc | $25 → $22 | Maintains | Overweight |
| 11/10/2021 | — | UBS | Downgrades | Buy → Neutral | |
| 11/10/2021 | 1900% | Truist Securities | → $12 | Downgrades | Buy → Hold |
| 11/10/2021 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 11/10/2021 | 2233.33% | B. Riley Securities | → $14 | Downgrades | Buy → Neutral |
| 11/10/2021 | 4066.67% | Keybanc | $33 → $25 | Maintains | Overweight |
| 11/08/2021 | 2566.67% | B of A Securities | $36 → $16 | Downgrades | Buy → Underperform |
| 10/04/2021 | 5900% | Keybanc | $40 → $36 | Maintains | Overweight |
| 09/28/2021 | 3566.67% | Craig-Hallum | $34 → $22 | Downgrades | Buy → Hold |
| 08/11/2021 | 5566.67% | Roth Capital | $31 → $34 | Maintains | Buy |
| 07/01/2021 | 5066.67% | Roth Capital | $37 → $31 | Maintains | Buy |
| 06/30/2021 | 5733.33% | Raymond James | $38 → $35 | Maintains | Outperform |
| 05/18/2021 | 6066.67% | Roth Capital | $35 → $37 | Maintains | Buy |
| 05/18/2021 | 6233.33% | Raymond James | $32 → $38 | Maintains | Outperform |
| 03/05/2021 | 5233.33% | Raymond James | $36 → $32 | Maintains | Outperform |
| 03/05/2021 | 6566.67% | Keybanc | $43 → $40 | Maintains | Overweight |
| 02/09/2021 | 7066.67% | Keybanc | $38 → $43 | Maintains | Overweight |
| 01/14/2021 | 6233.33% | KeyBanc | $34 → $38 | Maintains | Overweight |
| 11/10/2020 | 5566.67% | Keybanc | $26 → $34 | Maintains | Overweight |
| 10/26/2020 | 5900% | Raymond James | $28 → $36 | Maintains | Outperform |
| 08/14/2020 | 4566.67% | Raymond James | $19 → $28 | Maintains | Outperform |
| 08/14/2020 | 4233.33% | Keybanc | $22 → $26 | Maintains | Overweight |
| 08/03/2020 | 4900% | Craig-Hallum | → $30 | Initiates Coverage On | → Buy |
| 07/24/2020 | 3566.67% | Keybanc | $18 → $22 | Maintains | Overweight |
| 06/16/2020 | 3733.33% | B. Riley Securities | → $23 | Initiates Coverage On | → Buy |
| 06/11/2020 | 3066.67% | Raymond James | $16 → $19 | Maintains | Outperform |
| 06/10/2020 | 2900% | Keybanc | $16 → $18 | Maintains | Overweight |
| 05/12/2020 | 2733.33% | Wedbush | $11 → $17 | Maintains | Outperform |
| 05/12/2020 | 2566.67% | Raymond James | $10 → $16 | Maintains | Outperform |
| 05/12/2020 | 2566.67% | Keybanc | $12 → $16 | Maintains | Overweight |
| 03/31/2020 | 1900% | Keybanc | $14 → $12 | Maintains | Overweight |
| 03/10/2020 | 2233.33% | Wedbush | $13 → $14 | Maintains | Outperform |
| 02/14/2020 | 3066.67% | Oppenheimer | $15 → $19 | Maintains | Outperform |
| 01/27/2020 | 2233.33% | Keybanc | $12 → $14 | Maintains | Overweight |
| 01/16/2020 | 2066.67% | Raymond James | $11 → $13 | Maintains | Outperform |
| 01/14/2020 | 2066.67% | Wedbush | $12 → $13 | Maintains | Outperform |
| 12/19/2019 | 1566.67% | B of A Securities | → $10 | Initiates Coverage On | → Buy |
| 11/26/2019 | 1733.33% | Raymond James | → $11 | Initiates Coverage On | → Outperform |
| 11/25/2019 | 1900% | Keybanc | → $12 | Initiates Coverage On | → Overweight |
| 10/28/2019 | 1566.67% | Roth Capital | → $10 | Initiates Coverage On | → Buy |
| 09/23/2019 | 1900% | Wedbush | $9 → $12 | Maintains | Outperform |
| 11/15/2018 | 983.33% | Wedbush | $8 → $6.5 | Maintains | Outperform |
What is the target price for Purple Innovation (PRPL)?
The latest price target for Purple Innovation (NASDAQ: PRPL) was reported by Oppenheimer on November 13, 2023. The analyst firm set a price target for $0.00 expecting PRPL to fall to within 12 months (a possible -100.00% downside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Purple Innovation (PRPL)?
The latest analyst rating for Purple Innovation (NASDAQ: PRPL) was provided by Oppenheimer, and Purple Innovation downgraded their perform rating.
When is the next analyst rating going to be posted or updated for Purple Innovation (PRPL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Purple Innovation, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Purple Innovation was filed on November 13, 2023 so you should expect the next rating to be made available sometime around November 13, 2024.
Is the Analyst Rating Purple Innovation (PRPL) correct?
While ratings are subjective and will change, the latest Purple Innovation (PRPL) rating was a downgraded with a price target of $0.00 to $0.00. The current price Purple Innovation (PRPL) is trading at is $0.60, which is out of the analyst's predicted range.